| 摘要: |
| 狄诺塞单抗(Denosumab)是首个上市的抗RANKL治疗性单克隆抗体产品,主要用于治疗骨质疏松症和其他骨骼疾病。本文主要综述其近年国外治疗绝经后骨质疏松症的临床研究进展。 |
| 关键词: Denosumab 核因子κB受体活化因子配体 绝经后骨质疏松症 临床研究 |
| DOI:10.13506/j.cnki.jpr.2017.10.011 |
| 基金项目: |
|
|
|
| Clinical research progress of Denosumab for the treatment of postmenopausal osteoporosis |
| ZHANG Yijia,LUO Liping1,LIU Yanzhi2 |
| (1.Livzon Mabpharm Inc.,Zhuhai 519045,China;2.Guangdong Key Laboratory for R&D of Natural Drugs,Guangdong Medical University,Zhanjiang 524023,China) |
| Abstract: |
| Denosumab is the first marketed product of anti-Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) monoclonal antibody for the treatment of osteoporosis and other bone diseases.The clinical research progress of Denosumab for the treatment of postmenopausal osteoporosis was reviewed in this article. |
| Key words: Denosumab RANKL Postmenopausal osteoporosis Clinical study |